A shot being developed by AstraZeneca and the University Off Oxford produces a strong immune response in older adults.

阿斯利康公司和牛津大學正在開發的一種針劑能使老年人產生強烈的免疫反應。

That is, according to data from mid stage trials.

也就是說，根據中期試驗的數據。

They involved 560 healthy volunteers aged from 18 to 70 and over.

他們涉及560名18歲至70歲以上的健康志願者。

The volunteers reported no serious side effects.

志願者報告說，沒有嚴重的副作用。

Now, researchers say the results suggest that older folk can build robust immunity.

現在，研究人員說，結果表明，老年人可以建立強大的免疫力。

Further trials will aim to confirm the findings and test whether the vaccine can even protect those with underlying health conditions.

進一步的試驗將旨在證實這些發現，並測試疫苗是否甚至可以保護那些有潛在健康狀況的人。

A report in The Lancet medical journal says initial results from the late stage tests could be possible in the coming weeks.

柳葉刀》醫學雜誌的一份報告稱，未來幾周內可能會有後期測試的初步結果。

The Oxford AstraZeneca offering had Bean seen as among the front runners for an effective treatment, but recent weeks have seen rival drug makers Pfizer by on tech and Moderna edge ahead.

牛津阿斯利康的產品曾豆被視為有效治療的前鋒之一，但最近幾周看到競爭對手的藥物製造商輝瑞由在技術和Moderna邊緣領先。